





































 CURRENTOPINION Primary biliary cholangitis: pathogenic mechanisms
Jesús Prietoa, Jesus M. Banalesb,c,d, and Juan F. Medinae
Purpose of review
Primary biliary cholangitis (PBC) is characterized by autoimmune damage of intrahepatic bile ducts
associated with a loss of tolerance to mitochondrial antigens. PBC etiopathogenesis is intriguing because of
different perplexing features, namely: a) although mitochondria are present in all cell types and tissues,
the damage is mainly restricted to biliary epithelial cells (BECs); b) despite being an autoimmune disorder,
it does not respond to immunosuppressive drugs but rather to ursodeoxycholic acid, a bile salt that induces
HCO3
 rich choleresis; c) the overwhelming female preponderance of the disease remains unexplained.
Here we present an etiopathogenic view of PBC which sheds light on these puzzling facts of the disease.
Recent findings
PBC develops in patients with genetic predisposition to autoimmunity in whom epigenetic mechanisms
silence the Cl/HCO3
 exchanger AE2 in both cholangiocytes and lymphoid cells. Defective AE2 function
can produce BECs damage as a result of decreased biliary HCO3
 secretion with disruption of the
protective alkaline umbrella that normally prevents the penetration of toxic apolar bile salts into
cholangiocytes. AE2 dysfunction also causes increased intracellular pH (pHi) in cholangiocytes, leading to
the activation of soluble adenylyl cyclase, which sensitizes BECs to bile salt-induced apoptosis. Recently,
mitophagy was found to be inhibited by cytosolic alkalization and stimulated by acidification. Accordingly,
we propose that AE2 deficiency may disturb mitophagy in BECs, thus, promoting the accumulation of
defective mitochondria, oxidative stress and presentation of mitochondrial antigens to the immune cells. As
women possess a more acidic endolysosomal milieu than men, mitophagy might be more affected in
women in an AE2-defective background. Apart from affecting BECs function, AE2 downregulation in
lymphocytes may also contribute to alter immunoregulation facilitating autoreactive T-cell responses.
Summary
PBC can be considered as a disorder of Cl/HCO3
 exchange in individuals with genetic predisposition
to autoimmunity.
Keywords
Ae2 KO mice, antimitochondrial antibodies, biliary bicarbonate umbrella, epigenetic mechanisms, female
predominance, miR-506, mitophagy, Naþ–independent Cl/HCO3
 anion exchanger 2, pHi disturbance,
promoter hypermethylation, soluble adenylyl cyclase
INTRODUCTION
Primary biliary cholangitis (PBC) is an autoimmune
disease that affects interlobular bile ducts causing
ductopenia and progressive cholestasis. It is character-
ized by the presence (in 95% of the patients) of anti-
mitochondrial antibodies (AMAs), overwhelming
female preponderance (10 :1) and frequent associa-
tion with sicca syndrome and other autoimmune
diseases, such as Hashimoto’s thyroiditis, reumathoid
arthritis andscleroderma [1–7]. PBC-specific AMAs are
directed against components of the 2-oxo dehydroge-
nase complexes, principally the inner lipoyl domain
in the E2 component of the pyruvate dehydrogenase
complex (PDC-E2), but also thebranched chain2-oxo-
aciddehydrogenase (BCOADC-E2)and2-oxoglutarate
dehydrogenase complex (OGDC-E2) [8,9]. Addition-
ally, andregardlessofAMAstatus,30%ofpatientsmay
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develop different PBC-specific antinuclear autoanti-
bodies presenting multiple nuclear-dot or nuclear-
membrane staining patterns [10]. These autoantibod-
ies include the highly specific anti-gp210 and anti-p62
(with 95% specificity for PBC each) as well as anti-
sp100, anti-PML and anti-sp140 [5,10].
PBC has variable presentation. Although there
are patients who evolve rapidly to advanced forms of
liver damage, in most cases, the progression is slow
with long lasting asymptomatic evolution in some
individuals [1]. However, if the disease is left
untreated, the persisting damage of bile ducts leads
to increasing cholestasis with jaundice, pruritus and
hypercholesterinemia, ending up in biliary cirrhosis
requiring liver transplantation [11,12].
Nowadays, growing clinical awareness and
widespread use of AMA test in the community allow
diagnosis of PBC at an early stage when daily admin-
istration of ursodeoxycholic acid (UDCA) is partic-
ularly efficient at improving biochemical markers,
attenuating bile duct injury and halting the evolu-
tion of the disease to advanced cholestasis and liver
failure [13–15]. Indeed, PBC patients who respond
favorably to UDCA (more than 60%) have a life
expectancy similar to that of age and sex-matched
normal population [16–18]. With ongoing develop-
ment of novel therapies, combination regimes are
expected to achieve adequate control of the disease
in those patients who do not respond to UDCA
alone [11,19,20]. In fact, sufficiently powered phase
III clinical trials have shown that two drugs, the FXR
agonist obeticholic acid and bezafibrate (a PPAR-a
agonist that reduces bile salt synthesis and increases
biliary phospholipid secretion), provide benefit in
combination with UDCA to patients with incom-
plete response to UDCA monotherapy [11,19].
PATHOLOGIC FINDINGS AND
IMMUNOLOGICAL MECHANISMS
The distinctive pathological finding in PBC is the
presence of dense portal and periportal inflamma-
tory infiltrates surrounding the small and medium-
sized intrahepatic bile ducts. Inflammatory cells
permeate the biliary epithelium, which appears
disrupted, with irregularities of the biliary lumen.
The inflammatory infiltrate is composed mainly of
CD4þ and CD8þ T cells, macrophages, B lympho-
cytes, plasma cells, NK and NKT cells, and variable
presence of eosinophils [21]. Infiltrating CD8þ T
cells exert a direct cytotoxic attack on bile duct
epithelium, whereas CD4þ cells are helper T (Th)
cells that act by producing inflammatory cytokines,
which stimulate autoreactive cytotoxic CD8þ T
cells and autoantibody production by B cells
[22,23
&&
]. As a reflection of the loss of tolerance to
PDC-E2, CD4þ and CD8þ T cells reacting against
this mitochondrial protein are abundantly found in
the liver of patients with PBC and, interestingly,
both B and T-cell epitopes include the lipoyl
domain of E2 [24]. Regulatory T cells (Treg) are
reduced in the liver and peripheral blood of patients
with PBC [25], a defect which likely facilitates
autoimmune responses.
In PBC, B-cell follicles are frequently observed in
the portal tract in the vicinity of biliary ducts. These
lymphocytic aggregates – which are termed tertiary
lymphoid structures (TLSs) when present outside
secondary lymphoid organs – can be found in the
target tissues of other autoimmune diseases. They
are characterized by the presence of high endothe-
lial cell venules and an organized disposition of B
and T cells in connection with follicular dendritic
cells. TLSs provide a cytokine and chemokine-rich
milieu, where B cells, follicular dendritic cells and T
cells interact enabling affinity maturation of effector
immune cells fostering humoral and cellular auto-
immunity [26]. It should be mentioned that early
PBC is characterized by IL-12-driven Th1 type of
immune response, whereas IL-23-mediated Th17
type of response prevails in later stages promoting
fibrosis in advanced disease [27].
Although PBC-specific AMA are not directly
pathogenic, immunocomplexes formed by AMA
and the cognate antigen can activate local and
regional dendritic cells boosting immunity against
E2 subunit. In fact, it has been shown that macro-
phages from PBC patients, but not from normal
individuals, produce high amounts of proinflamma-
tory cytokines, including IL-6, TNFa and IL-12,
when incubated with apoptotic bodies from BECs





 PBC arises as a result of epigenetic downregulation of
AE2 in both cholangiocytes and lymphoid cells in
patients with genetic predisposition to autoimmunity.
 AE2 deficiency in cholangiocytes has two main
consequences: it reduces biliary bicarbonate secretion,
which disrupts the protective alkaline umbrella with
subsequent penetration of protonated bile salts into
biliary epithelium and it induces an increase of pHi,
which favors cell apoptosis via sAC activation.
 It is proposed that pHi elevation in cholangiocytes
would impair mitophagy leading to oxidative stress,
accumulation of defective mitochondria, enrichment in
PDC-E2 and presentation of mitochondrial antigens to
the immune system provoking loss of immune tolerance
to mitochondrial proteins and production of AMA.
Biliary tract
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Notably, PDC-E2 is upregulated in injured
BECs and, because of its lack of glutathiolation,
it may remain intact in apoptotic bodies from
these cells [29,30,31
&
]. The apoptotic blebs of dam-
aged BECs can be engulfed by antigen-presenting
cells to stimulate adaptive immunity against this
mitochondrial antigen particularly when the indi-
vidual has a genetic background predisposing
to autoimmunity.
The question arises as to what is the basic alter-
ation of BECs that causes cell stress, PDC-E2 enrich-
ment and apoptosis.
BILIARY EPITHELIAL CELL DYSFUNCTION
IN PRIMARY BILIARY CHOLANGITIS: AN
ESSENTIAL DETERMINANT OF BILIARY
EPITHELIAL CELL STRESS LEADING TO
IMMUNE-MEDIATED BILE DUCT INJURY
BECs are polarized cells, which play a central role in
bile formation by secreting HCO3
 and water to the




represent about 3–5% of total liver cell population,
they generate 25–40% of total bile flow in humans,
indicating how active are these cells at transporting
water and HCO3
 to bile [32
&&
,33,35].
Ductular secretion of HCO3
 takes place via the
Cl/HCO3
 exchanger AE2 (also known as SLC4A2)





]. Notably, AE2 mRNA levels are
much higher in cholangiocytes than in hepatocyes
[39]. During the postprandial period, the gastroin-
testinal hormone secretin binds the secretin recep-
tor at the basolateral membrane of BECs resulting in
increased intracellular cAMP levels with subsequent
PKA activation and transfer of cytoplasmic vesicles
containing AE2, the Cl channel cystic fibrosis
transmembrane regulator (CFTR) and the water
channel aquaporin 1 (AQP1) to the luminal mem-
brane [40]. This event promotes CFTR-mediated exit
of Cl to the lumen, generating a Cl gradient,
which stimulates Cl/HCO3
 exchange via AE2,
leading to increased biliary HCO3
 and water secre-
tion [32
&&
,33,41]. CFTR also mediates ATP release to
bile [42]. Luminal ATP stimulates apical P2Y recep-
tors followed by activation of the apical, type III
inositol 1,4,5-triphosphate receptor (InsP3R, a Ca2þ
release channel present at the endoplasmic reticu-
lum) with subsequent rise of intracellular Ca2þ lev-
els. Increased intracellular Ca2þ enhances luminal
Cl gradient by activating the apical Ca2þ-depen-
dent Cl channel TMEM16A, thus, promoting AE2-
mediated Cl/HCO3
 exchange and biliary HCO3

secretion [42]. Acetylcholine can also stimulate bili-
ary HCO3
 secretion via activation of basolateral
InsP3Rs (types I and II) and elevation of intracellular
Ca2þ [42].
AE2 deficiency in primary biliary cholangitis
In the early 1990s, it was shown that PBC patients
exhibit reduced AE2 mRNA levels in the liver and in
peripheral blood mononuclear cells [43
&&
]. Defective
hepatic AE2 expression in PBC was corroborated by
immunohistochemistry studies demonstrating
reduced AE2 staining at the apical membrane of
BECs of interlobular bile ducts [38
&&
]. Notably, it
was found that UDCA therapy improved hepatic





]. Consistent with the concept that
PBC is associated with deficient HCO3
 transport to
bile, PET imaging revealed that secretin-induced
biliary HCO3
 secretion was impaired in PBC
patients and that UDCA therapy corrected this
defect [44
&&
]. In-vitro studies using isolated cholan-
giocytes further confirmed diminished AE2 activity
in specimens from individuals with PBC [45].
The notion that AE2 deficiency is central in the
pathogenesis of PBC was supported by findings in
Ae2a,b knockout mice. These animals recapitulate
most features observed in PBC patients, including
development of AMA, increased IgM levels, dis-
turbed immunoregulation, progressive cholestasis
and nonsuppurative cholangitis [46–48]. In fact,
all aged Ae2a,b knockout mice (15–25 months)
exhibit portal mononuclear infiltration with abun-
dant cytotoxic lymphocytes, bile duct damage and
ductopenia [47]. Moreover, Ae2a,b-deficient mice
manifest an altered cholangiocyte gene expression
profile consistent with the existence of oxidative
stress and enhanced antigen presentation [46].
Upregulation of miR-506 in primary biliary
cholangitis cholangiocytes
In the last years, it was found that miR-506 (has-
miR-506–3p/5p), a micro RNA that targets both AE2
and InsP3R3, is upregulated in BECs from PBC
patients compared with either patients with primary
sclerosing cholangitis or healthy controls [49,50].
Noteworthy, transfection of PBC cultured cholan-
giocytes with antimiR-506 oligonucleotides
increases AE2 activity [49], whereas experimental
overexpression of miR-506 in cholangiocytes dimin-
ishes AE2 expression and activity, causes PDC-E2
overexpression, impairs mitochondrial energy
metabolism and promotes oxidative stress, endo-
plasmic reticulum stress and bile acid induced-apo-
ptosis [31
&
]. Moreover, lymphocytes from PBC
patients are activated and proliferate when cocul-
tured with miR-506-overexpressing cholangiocytes
Primary biliary cholangitis Prieto et al.
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[31
&
]. Accordingly, in PBC patients, the upregula-
tion of miR-506 in cholangiocytes might impair
biliary HCO3
 secretion while promoting a proin-
flammatory and immunogenic phenotype in BECs.
Of interest, the MiR-506 gene is located in the X
chromosome, a fact that might be related to the
female predominance observed in PBC [49]. Of note,
proinflammatory cytokines stimulate MiR-506 pro-
moter activity [31
&
], suggesting that inflammatory
processes generated by environmental factors might
contribute to AE2 downregulation in the biliary
epithelium of PBC patients via increased miR-
506 expression.
AE2 deficiency increases pHi, enhances the
sensitivity to proapoptotic signaling and may
potentially affect mitophagy in BECs
In addition to be a crucial mediator of biliary HCO3

secretion, AE2 is an acid loader involved in regulat-
ing intracellular pH (pHi) [41]. Accordingly, AE2
dysfunction in BECs results in increased pHi
[41,48,49]. Notably, it was found that intracellular
alkalization activates the HCO3
 sensor soluble




In addition, deficient AE2 activity might likely
impinge on a variety of cell functions, including
autophagy and mitophagy, which are processes crit-
ically dependent on pHi [53
&&
]. In particular,
mitophagy, the specific autophagic elimination of
mitochondria, is induced by cytosolic acidification,
whereas intracellular alkalization impairs this pro-
cess, ultimately leading to the accumulation of
defective mitochondria, production of reactive oxy-
gen species and activation of cell death pathways
[53
&&
,54]. When dysfunctional mitochondria are not
properly eliminated, the activation of intracellular
innate immunity sensors, such as the NLRP3 inflam-
masome, stimulates the production of proinflam-
matory cytokines, such as IL-1b and IL-18 [55
&
,56].
Thus, mitophagy represents a critical cell-intrinsic,
quality-control and anti-inflammatory mechanism,
which is likely disturbed in PBC BECs. Defective
mitophagy would make these cells to overexpress
mitochondrial antigens and to acquire a proinflam-
matory and immunogenic phenotype. Importantly,
Matheoud et al. [57
&&
] showed that the blockade of
mitophagy was accompanied by presentation of
high levels of mitochondrial antigens on major
histocompatibility complex class I, an observation
which is clearly relevant to the pathogenesis of PBC.
The potential involvement of dysregulated
mitophagy in the pathogenesis of PBC is attractive
as it might explain the enrichment of BECs in mito-
chondrial proteins and their increased presentation
to the immune system. Interestingly, it has been
recently shown that there are sex differences in the
pH of intraphagolysosomal milieu, which is more
acidic in women than in men [58
&&
]. Accordingly, it
would be expected that defects in acidifiers like AE2
might affect mitophagy to a greater extent in
women. Moreover, mitochondrial dynamics have
been found to be markedly influenced by sex hor-
mones [59]. PBC is characterized by an overwhelm-
ing female preponderance and although
autoimmune diseases are in general more common
in women than in men, it is tempting to hypothe-
size that a preferential disturbance of mitophagy in
women in a context of defective AE2 function might
contribute to explain the strong female bias of
the disease.
Defective ‘biliary bicarbonate umbrella’ in
primary biliary cholangitis
As indicated above, in addition to disturbing the
intracellular milieu of cholangiocytes, impaired AE2
expression results in reduced alkalization of bile.
Ten years ago, Beuers et al. [60] proposed that the
bile duct epithelium is protected against the toxic
effects of bile salts by the presence of a HCO3
–rich
glycocalyx covering the luminal pole of cholangio-
cytes (a protective barrier designated as the ‘biliary
bicarbonate umbrella’). This alkaline protective bar-
rier is generated by the active AE2-mediated secre-
tion of HCO3
 to bile. Thanks to this alkaline shield,
glycine-conjugated bile salts with a pKa of 4, like
glycochenodeoxycholic acid, are maintained in a
polar membrane-impermeant form and therefore
are not able to enter BECs [60,61
&&
]. When AE2
activity is impaired, glycine-conjugated bile salts
remain in an apolar state and penetrate into chol-
angiocytes promoting oxidative stress, cell senes-
cence and apoptosis [51,62,63
&
].
The therapeutic effect of ursodeoxycholic
acid
UDCA promotes biliary HCO3
 secretion and there-
fore strengthens the defensive alkaline barrier,
which protects BECs [61
&&
]. The fact that most
PBC patients have a positive response to UDCA
while immunosuppressive drugs (including newer
biologics used to modify the immune system) do not
provide a clear benefit [19,64–68] supports the
notion that AE2 deficiency and a defective biliary
HCO3
 umbrella are key determinants of bile duct
damage in PBC. The mechanisms by which UDCA
increases biliary HCO3
 secretion involve the acti-
vation of PI3K/Akt pathway, which stimulates the
release of ATP leading to the extrusion of Cl to the
Biliary tract
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lumen through the Ca2þ-dependent Cl channel




]. In addition, UDCA upregulates AE2 gene
expression when acting in conjunction with gluco-
corticoids [69]. Moreover, UDCA induces nitric
oxide synthase in liver tissue and promotes Mrp2-
mediated canalicular secretion of nitric oxide in the
form of S-nitrosoglutathione (GSNO), a compound
that displays potent antiapoptotic effects on BECs
[70]. Additionally, GSNO was shown to enhance
UDCA-mediated ATP release by cholangiocytes fur-




Abundant evidence has been accumulated support-
ing the view that PBC occurs as a result of a dys-
function of the biliary epithelium in individuals
with genetic predisposition to autoimmunity.
Genome-wide association studies [71,72] and dense
fine-mapping association analysis [73] have related
susceptibility to PBC with variations in genes regu-
lating innate and adaptive immunity, similarly to




ies in discordant monozygotic twins showing differ-
ences in gene expression profile and DNA
methylation [74,75] indicate that besides genetics,
epigenetic factors contribute to the development of
the disease.
Concerning AE2 gene variations, conventional
genotyping of selected single nucleotide polymor-
phisms (rs2069443, rs2303933, rs2303937 and
rs2303941) in Japanese PBC patients revealed asso-
ciations with disease susceptibility and/or anticen-
tromere antibody production [76]. In whites,
however, no association of AE2 single nucleotide
polymorphisms with PBC susceptibility was found,
though two variants were reported to influence
AMA status [77], whereas the synonymous variation
rs2303932 was associated with reduced PBC progres-
sion in French patients receiving UDCA [78].
Environmental and epigenetic factors
Environmental elements may affect the phenotype
of patients, particularly via epigenetic changes
(DNA methylation patterns, noncoding RNAs like
microRNAs and noncoding long RNAs, histone
modifications, such as acetylation, methylation,
phosphorylation, ubiquitination and sumoylation)
leading to disturbed gene expression. So far, a sig-
nificant number of epigenetic changes have been
reported in PBC, which include altered expression
of microRNAs (thoroughly reviewed by Rodrigues
et al. [4]) as well as methylation abnormalities of
genes (either hyper or hypomethylation) on the
X chromosome and autosomal chromosomes
[4,23
&&
,74,79]. When affecting promoter regions,
hypermethylation is consistently related to silenc-
ing of gene expression, whereas hypermethylation
in intragenic regions is usually associated with
enhanced expression [80].
Recently, we reported that there is a significant
increase in CpG-cytosine methylation affecting
selective promoter regions of the AE2 gene both
in liver and PBMCs from PBC individuals [81
&
].
Moreover, mean methylation rates inversely corre-
late with mRNA levels [81
&
]. Of note, selective CpG-
hypermethylation clusters in PBC affected relevant
nuclear factor sites/motifs [81
&
,82–84].
Among environmental exposures affecting DNA
methylation, smoking has been associated with high
risk of PBC [85–87], being also related to increased
DNA-methyltransferase expression [88]. Therefore,
DNA methylation affecting AE2 and additional genes
may constitute a link between genetic and environ-
mental risk factors in PBC pathogenesis.
THE ROLE OF AE2 DEFICIENCY IN THE
DYSREGULATION OF IMMUNE RESPONSE
As mentioned, in PBC, AE2 mRNA levels are
decreased not only in the liver but also in peripheral
lymphoid cells [43
&&
]. Thus, altered pHi because of
defective AE2 activity may affect the function of
immune cells in PBC patients [48,89]. Indeed, we
found that Ae2a,b-deficient mice exhibit reduced
Treg population, progressive expansion of CD8þ T
cells and increased production of IL-12 and IFNg
[46,47]. Notably, we observed that CD4þ T cells
express several transporters that mediate cytosolic
acidification, including AE2, AE1 and Naþ–HCO3

cotransporter, whereas the last two are poorly
expressed in CD8þ T cells. Thus, CD8 T cells rely
heavily on AE2 for intracellular acidification.
Accordingly, AE2-deficient CD8þ T cells have high
pHi and, upon stimulation, become more alkaline,
produce more IL-2 and exhibit increased prolifer-
ative response [48]. These findings suggest that AE2
deficiency in lymphoid cells might contribute to
dysregulated T-cell responses in PBC patients.
PBC is characteristically a disease affecting mid-
dle-aged women. Data from Ae2a,b-knockout mice
illuminate the effect of age in the development of the
disease [47]. In young Ae2a,b-knockout mice, portal
tracts were infiltrated with activated T cells express-
ing PD1 and producing high amounts of IFNg (this
cytokine induces PD-L1 expression in cholangiocytes
Primary biliary cholangitis Prieto et al.
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and in other cell types of the portal tract). In young
knockout animals, the clonal expansion of autoreac-
tive lymphocytes within the liver was inhibited by
PD1/PD-L1 interaction. In contrast, in old Ae2a,b-
knockout mice, PD1 gene expression was epigeneti-
cally silenced by DNA methylation in CD8þ T cells.
This age-related epigenetic downregulation of PD1
allowed autoreactive CD8þ T cells to escape PD1/PD-
L1-induced apoptosis, favoring clonal expansion and
enhanced lymphocytic infiltration of portal tracts
with aggravation of bile duct lesion. Similar epige-
netic changes in patients with PBC would explain
why this disease is commonly manifested later in life,
between 40 and 60 years of age.
CONCLUSION
PBC results from autoimmune attack to the epithe-
lium of interlobular bile ducts. PBC develops in
patients with a genetic background predisposing
to autoimmunity. The target of the autoimmune
reaction is the mitochondrial antigen E2 compo-
nent of the 2-oxo dehydrogenase complexes, in
particular PDC-E2, which is overexpressed by
stressed BECs. The immune-mediated cholangiocel-
lular injury appears to be secondary to the failure of
BEC to secrete HCO3
 to bile due to AE2 deficiency.
This defect is likely because of epigenetic factors
involving miR-506 upregulation and AE2 promoter
methylation. Impaired biliary HCO3
 secretion dis-
rupts the defensive bicarbonate umbrella allowing
the penetration of hydrophobic bile acids into BECs
resulting in senescence and apoptosis of these cells.
In addition, AE2 deficiency alters cholangiolar pHi
leading to sAC activation and increased sensitivity
to bile salt-induced apoptosis. Increased pHi likely
disturbs mitophagy, with resulting accumulation
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FIGURE 1. PBC: Etiopathogenic mechanisms. Epigenetic, genetic and environmental factors concur in causing PBC.
Epigenetic mechanisms (including microRNAs and promoter hypermethylation) induce downregulation of AE2 in both
cholangiocytes and lymphocytes. Defective AE2 function in cholangiocytes decreases biliary bicarbonate secretion while
increasing intracellular pH (pHi). The disruption of the protective bicarbonate umbrella allows penetration of apolar bile salts
into hepatocytes promoting cell apoptosis, which is favored by the activation of soluble adenylyl cyclase (sAC) because of the
elevation of pHi. This alteration may also affect mitophagy, especially in women (in whom the endolysosomal milieu is more
acidic than in men). Impaired mitophagy would lead to oxidative stress, accumulation of defective mitochondria, PDC-E2
overexpression and presentation of mitochondrial antigens to the immune system. These changes lead to immuno-mediated
cell damage specially in individuals with genetic predisposition to autoimmunity. On the other hand, AE2 deficiency in
lymphocytes, particularly in CD8 T cells, may contribute to enhance autoreactive T-cell responses.
Biliary tract
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oxidative stress while promoting the presentation of
mitochondrial antigens to the immune system. It
could be hypothesized that as women exhibit a
more acidic intraendolysosomal milieu than men,
AE2 deficiency may disturb mitophagy more
intensely in women, thus, contributing to explain
the marked predominance of the disease in women.
In PBC, AE2 deficiency also affects lymphocytes
likely cooperating to the immunological derange-
ment present in this condition. In summary, PBC
could be considered as a disease that occurs in
patients with genetic predisposition to autoimmu-
nity in which AE2 is epigenetically downregulated
both in liver and lymphoid cells. These concepts are
illustrated in Fig. 1.
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